The firm's financial position is characterized by an accumulated deficit of $140.6 million as of 2026Q1, which significantly erodes the equity base despite a manageable debt-to-equity ratio of 0.02.
| Total Current Assets | 63.55M | 48.96M | 30.95M | 13.4M | 2.64M | 18.41M | 204K | 19K | 29K |
| Cash & Short-Term Investments | 54.59M | 41.27M | 26.14M | 9.7M | 455K | 16.58M | 0 | 15K | 25K |
| Cash Only | 37.37M | 29.2M | 26.14M | 9.7M | 455K | 16.58M | 0 | 15K | 25K |
| Short-Term Investments | 17.21M | 12.07M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 8.96M | 7.69M | 939K | 325K | 159K | 126K | 204K | 4K | 0 |
| Total Non-Current Assets | 861K | 174K | 720K | 792K | 174K | 333K | 200K | 0 | 0 |
| Property, Plant & Equipment | 861K | 174K | 720K | 792K | 174K | 333K | 0 | 0 | 0 |
| Fixed Asset Turnover | 0.00x | - | - | 0.85x | 5.47x | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 200K | 0 | 0 |
| Total Assets | 64.41M | 49.13M | 31.67M | 14.19M | 2.82M | 18.74M | 204K | 19K | 29K |
| Asset Turnover | 0.00x | - | - | 0.05x | 0.34x | - | - | - | - |
| Asset Growth % | 183.92% | 55.16% | 123.16% | 403.58% | -84.97% | 9088.24% | 973.68% | -34.48% | - |
| Total Current Liabilities | 26.48M | 18.94M | 24.12M | 17.53M | 3.28M | 2.1M | 2.88M | 903K | 1.24M |
| Accounts Payable | 1.14M | 383K | 966K | 821K | 846K | 742K | 184K | 322K | 60K |
| Days Payables Outstanding | 1.38K | 244.4 | - | - | - | - | - | - | - |
| Short-Term Debt | 598K | 117K | 92K | 18K | 46K | 29K | 2.51M | 460K | 1.05M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 24.75M | 18.44M | 18.94M | 13.13M | 0 | -29K | 0 | 0 | 0 |
| Current Ratio | 2.40x | 2.59x | 1.28x | 0.76x | 0.81x | 8.75x | 0.07x | 0.02x | 0.02x |
| Quick Ratio | 2.40x | 2.59x | 1.28x | 0.76x | 0.81x | 8.75x | 0.07x | 0.02x | 0.02x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 217K | 0 | 117K | 466K | 0 | 155K | 0 | 0 | 0 |
| Long-Term Debt | 217K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 117K | 466K | 0 | 155K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 26.7M | 18.94M | 24.24M | 18M | 3.28M | 2.26M | 2.88M | 903K | 1.24M |
| Total Debt | 815K | 117K | 773K | 811K | 201K | 335K | 2.51M | 460K | 1.05M |
| Net Debt | -36.56M | -29.08M | -25.37M | -8.89M | -254K | -16.24M | 2.51M | 445K | 1.02M |
| Debt / Equity | 0.02x | 0.00x | 0.10x | - | - | 0.02x | - | - | - |
| Debt / EBITDA | -0.03x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 1.25x | - | - | - | - | - | - | - | - |
| Interest Coverage | -645.60x | -373.01x | -516.31x | -371.49x | -3008.67x | -14.95x | -8.28x | -14.58x | - |
| Total Equity | 37.7M | 30.2M | 7.43M | -3.81M | -466K | 16.48M | -2.67M | -884K | -1.21M |
| Equity Growth % | 527.89% | 306.37% | 295.09% | -717.38% | -102.83% | 717.15% | -202.15% | 26.7% | - |
| Book Value per Share | 0.16 | 0.19 | 1.11 | -1.55 | -0.31 | 14.12 | -1.75 | -1.04 | -1.52 |
| Total Shareholders' Equity | 37.7M | 30.2M | 7.43M | -3.81M | -466K | 16.48M | -2.67M | -884K | -1.21M |
| Common Stock | 25K | 22K | 114K | 35K | 15K | 15K | 9K | 8K | 34K |
| Retained Earnings | -140.65M | -127.83M | -101.27M | -64.54M | -34M | -15.94M | -5.92M | -3.66M | -1.49M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 6K | -1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Binary Regulatory Funding Risk
According to recent financial statements, Unicycive's cash position of $37.4 million as of 2026Q1 provides a limited buffer against ongoing clinical development costs, with the current ratio of 2.40 suggesting that while near-term obligations are covered, the company remains highly dependent on future external capital infusions.
The liquidity profile is characterized by a rapid depletion of cash reserves as the company approaches critical regulatory milestones. Investors should monitor the current ratio closely, as any significant deviation from the current trend may necessitate dilutive financing to maintain operations.
As reported in historical balance sheets, Unicycive's equity base has been severely impacted by an accumulated deficit of $140.6 million as of 2026Q1, reflecting the persistent operational losses inherent in a pre-revenue biotechnology firm focused on long-term clinical development and regulatory approval processes.
The negative trend in retained earnings underscores the company's reliance on equity financing to sustain its research pipeline. This structural reliance on capital markets suggests that shareholder value remains highly sensitive to the timing and pricing of future equity offerings.
Based on the provided quarterly data, Unicycive's balance sheet trajectory appears increasingly strained, with total assets fluctuating significantly and equity volatility highlighting the company's vulnerability to the high costs associated with advancing its lead candidate, Renazorb, through the final stages of the regulatory pathway.
The lack of revenue generation means that asset growth is primarily driven by financing activities rather than operational success. This trajectory warrants further investigation into how management plans to bridge the gap between current clinical-stage status and potential commercialization without further eroding shareholder equity.
As disclosed in recent SEC filings, the company's reliance on minimal debt and heavy equity financing creates a misleadingly clean leverage profile, masking the underlying risk that the firm lacks the non-dilutive capital access required to survive a potential regulatory delay or commercial launch failure.
While the low debt-to-equity ratio might appear favorable, it is a byproduct of the company's inability to access traditional credit markets due to its pre-revenue status. Investors should be wary of interpreting this lack of leverage as financial strength, as it actually reflects a lack of operational cash flow.
Quick answers to the most common questions about buying UNCY stock.
As of 2025, Unicycive Therapeutics, Inc. (UNCY) had total assets of $49.1M including $49.0M in current assets.
Unicycive Therapeutics, Inc. (UNCY) carries total debt of $0.1M, offset by $41.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Unicycive Therapeutics, Inc. (UNCY) has total shareholders' equity (book value) of $30.2M ($0.19 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Unicycive Therapeutics, Inc. (UNCY) reported a current ratio of 2.59x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.